CAR-NK cell therapy for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and preliminary efficacy of CAR-NK cells targeting Claudin6, GPC3, Mesothelin, or AXL in patients with advanced solid tumors, including ovarian and testis cancers. Patients will undergo apheresis to collect NK cells, which will then be genetically modified to express CARs targeting specific tumor markers. The modified NK cells will be expanded and infused back into the patients, with close monitoring of their response and safety. The study aims to explore the potential of this innovative therapy in treating advanced cancers that express these targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. patients with advanced ovarian cancer or other cancers with expression of claudin6.
2. Life expectancy \>12 weeks
3. Adequate heart,lung,liver,kidney function
4. Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6, GPC3, Mesothelin, or AXL-CAR determined by flow-cytometry and killing of claudin6-positive targets greater than or equal to 20% in cytotoxicity assay
5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. -

Exclusion Criteria:

1. Had accepted gene therapy before;
2. Tumor size more than 25cm;
3. Severe virus infection such as HBV,HCV,HIV,et al
4. Known HIV positivity
5. History of liver/renal transplantation
6. Active infectious disease related to bacteria, virus,fungi,et al
7. Other severe diseases that the investigators consider not appropriate;
8. Pregnant or lactating women
9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day)
10. Other conditions that the investigators consider not appropriate. -

Where it's running

• The Second Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Zhenfeng Zhang, MD, PHD — Second Affiliated Hospital of Guangzhou Medical University
• Study coordinator: Zhenfeng Zhang, MD, PHD
• Email: zhangzhf@gzhmu.edu.cn
• Phone: +862039195966

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• OPB-201 therapy for recurrent endometrial and platinum-resistant ovarian cancer

  A one-time treatment with a patient’s own T cells engineered to target PRAME is being tested to see if it is safe and what dose works best for adults with recurrent endometrial cancer or platinum-resistant ovarian cancer.

  Recruiting at 5 sites Phase 1 Outpace Bio, Inc. · San Francisco, California and 4 other locations · NCT07664735

• Exploring personalized treatment for recurrent gynecological cancers

  This study is testing if using genetic information to guide treatment can help improve outcomes for people with recurrent ovarian, cervical, or endometrial cancer.

  Recruiting at 2 sites Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT06781151

• Testing a new dosing method of niraparib for ovarian cancer treatment

  This study is testing a new way to give niraparib to see if it helps people with newly diagnosed advanced ovarian cancer stay healthy longer after their initial chemotherapy.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT05961124

• Heated chemotherapy followed by Niraparib for advanced ovarian cancer

  This study is testing if a heated chemotherapy treatment followed by a drug called Niraparib can help people with advanced ovarian cancer do better after surgery compared to regular chemotherapy.

  Recruiting at 59 sites Phase 3 GOG Foundation · Duarte, California and 58 other locations · NCT05659381

• Comparing stress reduction methods to standard care for ovarian cancer patients

  This study is testing if a mix of medications and therapies can help reduce stress in women with advanced ovarian cancer before their surgery, compared to those getting standard care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05429970

• Optimizing hormonal therapy for advanced and recurrent endometrial cancer

  This study is trying to find better ways to use hormonal therapy for women with advanced or recurring endometrial cancer by looking at their tumor samples to see who might benefit most from this treatment.

  Recruiting Radboud University Medical Center · Nijmegen · NCT03621904

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.